Which drug class does Trabectedin belong to?

Trabectedin is an innovative anti-cancer drug derived from marine organisms. It was originally isolated from Caribbean sheaths and is regarded as a model for the successful application of marine natural products in tumor treatment. In terms of pharmacological classification, it is classified into the alkylating drug class, but its mechanism is significantly different from traditional alkylating agents.

Traditional alkylating drugs mostly block replication by directly forming cross-linking points onDNA chains, while trabectedin forms adducts with guanine residues in a unique way by binding to the minor groove of DNA, causing DNA to undergo spatial conformation changes and bending the double helix structure toward the major groove. This special bend not only blocks DNA replication, but also interferes with the activity of various DNA-binding proteins, especially transcription factors and DNA repair pathways, causing irreversible damage to cancer cells during their division and eventual death.

Clinical application studies have shown that trabectedin shows good activity in refractory tumors such as soft tissue sarcoma and recurrent ovarian cancer, especially when conventional chemotherapy fails, providing new treatment possibilities. Unlike some molecular targeted drugs, trabectedin does not rely on specific gene mutations, but works through global gene transcription interference and DNA repair inhibition. This "multi-target" mechanism determines its potential application value in a variety of complex cancer types. From the perspective of molecular biology, it not only has the broad-spectrum cytotoxicity of chemotherapy drugs, but also exhibits the precision of molecular regulation.

Therefore, it is accurate to define trabectedin as an alkylating drug, but it is far from an alkylating agent in the traditional sense, but a new generation of anti-cancer drugs that integrates the dual mechanisms of DNA damage and transcriptional regulation. It is this differentiated mode of action that allows trabectedin to occupy a unique position in the anti-tumor drug spectrum, and it has also become one of the second-line and third-line treatment options recommended in international guidelines.

Reference materials:https://www.drugs.com/monograph/trabectedin.html